论文部分内容阅读
慢性乙型肝炎 (HBsAg+ ,HBeAg+ ,HBV -DNA+ ) 136例 ,随机分为 3组 ,第 1组 49例采用抗乙肝iRNA2mg隔日肌注 ,3个月 ,联合单磷酸阿糖腺苷 (ArA -AMP) 10mg/kg肌注 5天后 5mg/kg 2 3天 ,胸腺肽 10mg每日肌注30天。第 2组 45例用胸腺肽 90天 ,剂量和其他联合用药同 1组。第 3组 42例为对照组。治疗结束 (3个月 ) 3个组ALT复常率分别为 93 8% ,93 3% ,47 6 % ;HBeAg转阴率 32 7% ,37 8% ,9 4%HBV -DNA转阴率 34 0 % ,40 0 % ,2 4%。停药后随访一年 ,ALT复常率分别为 85 7% ,91 0 % ,5 0 0 %。HBeAg转阴率 30 6 % ,33 3% ,11 9%。HBV -DNA转阴率 30 6 % ,35 6 % ,11 9%。第 1、2两组各项与对照组比全部P <0 0 5 ,第 1与 2组各项目比P >0 0 5。提示这三种药联合治疗慢性乙型肝炎可取得部分病人持久疗效
Thirty-six patients with chronic hepatitis B (HBsAg +, HBeAg +, HBV-DNA +) were randomly divided into 3 groups. 49 patients in group 1 received intramuscular injection of anti-hepatitis B iRNA 2 mg every other day for 3 months. Combined with ArA-AMP ) 10mg / kg 5mg / kg 2 days after 5 days of intramuscular injection, Thymosin 10mg daily intramuscular injection for 30 days. The second group of 45 patients with thymosin 90 days, the dose and other combinations with the same group. 42 cases in the third group as the control group. At the end of treatment (3 months), the recovery rates of ALT in the three groups were 93.8%, 93.3% and 47.6% respectively; the HBeAg negative rates were 32.7%, 37.8% and 94.4% respectively 0%, 40 0%, 24%. After a year of follow-up after discontinuation of treatment, the recovery rates of ALT were 85.7%, 91.0% and 500% respectively. HBeAg negative rate of 30 6%, 33 3%, 11 9%. HBV-DNA negative rate of 30 6%, 35 6%, 11 9%. The first and second groups each compared with the control group all P <0 05, the first and the two groups than the project P> 0 0 5. Prompt combination of these three drugs in the treatment of chronic hepatitis B can be achieved in some patients lasting efficacy